Target Product Profiles

If you don’t know where you are going, how do you get there? The same applies to drug development. If you don’t know what drug you are making, or who you are making it for, how can you build it?

A target product profile (TPP)is a plain-language blueprint of the drug you intend to bring to patients It guides development activities and explains your drug concept to team members, partners, key opinion leaders (KOLs) and investors. TPPs capture the choices made about your drug and the patient population it will serve. Without that clarity, drug development planning is just guesswork.

TPPs Clarify

• What disease or disorder will the drug address?
• Which patient population and unmet medical need will it target?
• What is the mechanism of action?
• What efficacy and safety profile is required?
• How will the drug be administered?
• What quality standards must it meet?

Like a fine wine that must age to reach maturity, A TPP is a living document that becomes more refined as you generate more data and insights into your desired patient population.

TPPs are fundamentally strategic because they force you to make explicit choices about what you will and will not develop. They help set decisive Go/No-Go criteria, linking data readouts to decisions that move progress forward. They help ensure alignment between functions such as preclinical, manufacturing, clinical, and regulatory. In addition, they support the creation of preclinical study workflows and development roadmaps. Teams can further sharpen their investor-ready narrative with a clear drug development vision.

A well-crafted TPP demonstrates strategic clarity by laying out the choices you have made in a way that others can understand to gain stakeholders buy-in.

Having great scientific ideas is simply not enough. A structured approach to drug development is critical for transforming scientific innovations into a feasible strategy and actionable plan to build a drug product.

Everything is important! Those 3 mouse challenge studies must start this week! Update the investor deck and program dashboard for C-level TODAY. Get it all done!

Sound familiar? It seems like doing everything all at once is the new standard in drug development. Prioritizing activities in the right sequence brings clarity to your development path. The alternative, “Everything is a Priority”, creates confusion and erodes the team’s focus, resources, and productivity. Progress is not achieved by simply doing more stuff. A list of experiments doesn’t replace a cohesive drug development roadmap.

Success requires a relentless focus on generating the specific datasets that indicate your drug candidate is safe and has the potential to be clinically efficacious. Prioritize the following:

• Creating and refining your Target Product Profile (TPP) and drug concept.
• Developing milestones tied to metrics that meet your desired TPP parameters.
• Selecting the key experiments and activities to reach your milestones.
• Establishing priorities to clarify the sequence of activities.
• Communicating and aligning your choices with key stakeholders.
• Assigning tasks and executing.

If everything is a priority, nothing is a priority. Success is intricately linked to your team’s ability to separate the signal from the noise. What doesn't get communicated isn’t executed. Without a clear strategy and priorities, your ideas will remain as concepts.